MDSpire - MDSpire Home

MDSpire - MDSpire Home

Region

United States US publications and network International Global sites and content

The premier global destination for healthcare professionals looking for trusted clinical content, breaking news, and a wealth of educational resources.

Conexiant.com
Conexiant Education

Trusted by leading healthcare organizations to deliver measurable engagement, education, and brand growth.

Conexiant Solutions
Conexiant DXP

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

MDSpire.com
DentalSpire.com

Association Partner

Our vision is a world free from digestive diseases. That's why it's our mission to empower clinicians and researchers to improve digestive health.

gastro.org
agau.org.gastro
myaga.gastro.org
foundation.gastro.org
agajournals.org
healthecareers.com

Conexiant.com
Conexiant Education

Conexiant DXP

MDSpire.com
DentalSpire.com

gastro.org
myaga.gastro.org
agajournals.org
agau.org.gastro
foundation.gastro.org

Advertisement

What is MDSpire?

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

Learn More

Choose specialties Cardiology Dermatology Endocrinology Family Medicine Gastroenterology Hematology Internal Medicine Neurology ObGyn Oncology Ophthalmology Optometry Pediatrics Rheumatology Pulmonary Psychiatry Pathology Surgery Orthopedic Medicine Radiology Otolaryngology Infectious Disease

May 20, 2026

FDA Approves Expanded Liquid Biopsy Panel

Kathryn Wighton
May 20, 2026
2 min

Summary
Insight Report
Quiz

Objective: To inform about the FDA approval of the Guardant360 Liquid CDx assay for advanced cancer treatment selection. Key Findings: The assay is the largest

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

May 20, 2026

Grip Strength Plus Waist Size May Flag Risk T2d Risk

Andrea Surnit
May 20, 2026
5 min

Summary
Takeaways
Insight Report
Poll

Objective: To examine the relationship between waist circumference and grip strength in predicting the risk of developing type 2 diabetes (T2D). Key Findings: I

High waist circumference and low grip strength significantly increase the risk of developing type 2 diabetes, with a hazard ratio of 7.68.
Abdominal adiposity is the primary risk factor for diabetes, while lower grip strength offers additional, albeit modest, risk stratification.
The study analyzed data from 483,578 UK Biobank participants, making it the first large European cohort study on waist circumference and grip strength.
Women showed stronger associations between waist circumference and diabetes risk, with a hazard ratio of 10.24 for high waist and low grip strength.
The researchers emphasized that grip strength reflects overall muscular fitness rather than being a direct causal factor for diabetes risk.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

May 20, 2026

Combination Therapy Shows Potential in Psoriasis, Obesity

Kathryn Wighton
May 20, 2026
5 min

Summary
Quiz
Clinical Scorecard

Objective: To evaluate the efficacy of ixekizumab plus tirzepatide in achieving simultaneous complete skin clearance and weight reduction in adult patients with

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

May 20, 2026

ACS Collaborative May Improve Compliance in Lung Nodal Assessment

Andrea Surnit
May 20, 2026
4 min

Summary
Quiz

Objective: To evaluate the impact of a national quality-improvement collaborative on compliance with lung cancer surgical operative standards across US cancer p

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

May 20, 2026

CGRP Therapies Reduced Migraine Days

Andrea Surnit
May 20, 2026
3 min

Summary
Takeaways
Insight Report
Poll
Clinical Scorecard

Objective: To evaluate the effectiveness of calcitonin gene-related peptide (CGRP) targeted therapies in reducing monthly migraine headache days specifically in

CGRP-targeted therapies reduced monthly migraine headache days by about 2 days compared to placebo in chronic migraine patients.
The systematic review included 43 trials with 14,725 adult patients, establishing high-certainty evidence for several CGRP therapies.
Fremanezumab and erenumab showed high-certainty evidence for achieving at least a 50% reduction in migraine days.
Galcanezumab likely reduced dropout rates due to any cause, while erenumab and atogepant increased risks of constipation and nausea.
The review highlighted the need for larger independent trials to assess long-term safety and effectiveness of CGRP therapies.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

May 20, 2026

AI Drafts Cut Radiograph Reporting Time

Andrea Surnit
May 20, 2026
4 min

Summary
Insight Report
Quiz
Poll
Clinical Scorecard

Objective: To evaluate the impact of workflow-integrated generative AI on radiograph documentation efficiency and clinical accuracy, specifically focusing on pe

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

May 20, 2026

Ivarmacitinib Eased Refractory PCA: Case Report

Andrea Surnit
May 20, 2026
4 min

Summary
Takeaways
Poll

Objective: To report the effects of ivarmacitinib on a patient with treatment-refractory primary cutaneous amyloidosis, highlighting its potential as a novel th

A 65-year-old man with refractory primary cutaneous amyloidosis showed rapid improvement after off-label treatment with ivarmacitinib.
The patient experienced significant pruritus relief and lesion improvement within one month of starting ivarmacitinib.
Histopathologic examination confirmed the diagnosis of primary cutaneous amyloidosis, showing characteristic amyloid deposits.
Ivarmacitinib, a selective JAK1 inhibitor, may target multiple inflammatory pathways involved in pruritus and T helper 2 inflammation.
The study highlights the potential of ivarmacitinib for treating isolated primary cutaneous amyloidosis, warranting further research.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

May 20, 2026

Medical Oddities: Something Viral is Lurking in the Dust

Teraya Smith
May 20, 2026
5 min

Summary
Insight Report
Quiz

Objective: To identify the presence of viruses in dust samples collected from various public spaces. Key Findings: Identified viruses include SARS-CoV-2, influe

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

May 20, 2026

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Conexiant News Staff
May 20, 2026
3 min

Summary
Insight Report
Quiz
Clinical Scorecard

Objective: To investigate and report on the early signals of myocarditis following mRNA COVID-19 vaccination and the implications for public health communicatio

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Pathologist

May 20, 2026

Digital Pathology: the Great Translation Debate

Jessica Allerton
May 20, 2026
4 min

Summary
Insight Report
Quiz
Clinical Scorecard

Objective: To discuss the transition of pathology towards a digital future and the multifaceted role of AI in enhancing clinical practice and operational effici

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Ophthalmologist

May 20, 2026

Ocular Surface Optimization: The Best First Step in Modern Cataract Surgery

Jeff Banas
May 20, 2026
9 min

Summary
Quiz

Objective: To emphasize the importance of ocular surface optimization as a critical first step in refractive cataract surgery, directly linking it to enhanced p

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Pathologist

May 20, 2026

Can a Blood Count Predict Dementia?

May 20, 2026
2 min

Summary
Quiz

Objective: To investigate whether the neutrophil-to-lymphocyte ratio (NLR) can predict the risk of developing dementia. Key Findings: Higher NLR values are asso

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Analytical Scientist

May 20, 2026

Mass Spec Roundup: Structure Searching Comes to Metabolomics

May 20, 2026
6 min

Summary
Quiz

Objective: To introduce StructureMASST, a web tool that enhances the searchability of metabolomics data by chemical structure, significantly improving the acces

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Analytical Scientist

May 20, 2026

Why We’re Using AI to Rethink Analytical Chemistry Education

Paulo Correia
May 20, 2026
6 min

Summary
Takeaways
Insight Report
Poll

Objective: To explore the use of AI in identifying threshold concepts in analytical chemistry education that may be overlooked due to expert familiarity. Key Fi

AI is being used to identify threshold concepts in analytical chemistry education, which are crucial for transforming student understanding.
The project employs a two-stage AI workflow to analyze educational texts and surface candidate concepts for expert evaluation.
Threshold concepts, such as precision and accuracy, are essential for students to internalize the reasoning behind measurement and evidence.
AI helps reveal blind spots in expert consensus by detecting recurring conceptual tensions across multiple sources.
The ultimate goal is to enhance curriculum design by focusing on significant threshold concepts that impact students' practical reasoning.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

The Ophthalmologist

May 20, 2026

Rethinking Uveal Melanoma Surveillance

May 20, 2026
3 min

Summary
Takeaways
Quiz

Objective: To evaluate the duration and efficiency of hepatic surveillance needed after initial treatment for uveal melanoma. Key Findings: 29% of patients deve

A study of 1086 uveal melanoma patients suggests that hepatic surveillance may be effective for only five years post-treatment.
29% of patients developed liver metastases, with 93% detected within the first five years of surveillance.
Surveillance protocols currently impose significant imaging burdens, particularly with the use of MRI in resource-constrained systems.
Increasing T stage and tumor location significantly influence metastatic risk, indicating a need for tailored follow-up.
The study advocates for rethinking surveillance protocols to focus on personalized strategies rather than a one-size-fits-all approach.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Medicine Maker

May 20, 2026

Rethinking Progress in Clinical Trials

May 20, 2026
11 min

Summary
Takeaways
Poll

Objective: To explore the evolving landscape of clinical trials, focusing on meaningful progress, early signals, and the integration of preclinical and clinical

Meaningful progress in clinical trials emphasizes speed combined with direction to enhance decision-making and reduce patient wait times.
Early-stage studies must confirm preclinical biology translates into effective clinical protocols, ensuring safety and efficacy signals are clear.
Integration between preclinical and clinical teams fosters a continuous learning system, enhancing trial design and decision-making processes.
Regulatory expectations have evolved, with earlier engagement helping sponsors navigate challenges in demonstrating efficacy and safety.
Trust, inclusion, and operational discipline are now central to ethical research and the generation of high-quality data in clinical trials.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Frontiers In Oncology

May 20, 2026

Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy

Haruko Takuwa
Shoko Sasaki
Naoki Goda
Megumi Takeuchi
May 20, 2026

Summary
Takeaways
Insight Report
Quiz
Poll
Clinical Scorecard

Objective: To report a case of pregnancy-associated breast cancer in a BRCA1 pathogenic variant carrier and discuss the importance of individualized management

A 38-year-old woman with a BRCA1 variant was diagnosed with stage IIA breast cancer during her fifth pregnancy.
She underwent left total mastectomy at 18 weeks of gestation, followed by adjuvant chemotherapy after delivery.
The patient's family history included multiple cases of breast and ovarian cancer, highlighting her hereditary risk.
Risk-reducing salpingo-oophorectomy was performed after her pregnancy, with no malignant lesions found in the resected tissue.
Management of pregnancy-associated breast cancer should be individualized, considering safety and timing of interventions.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Frontiers In Pediatrics

May 20, 2026

Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers

Kriti Kumar
Avram Denburg
Celine Cressman
Derek S. Tsang
Marcel Romanick
Myanca Rodrigues
Paul J. Gibson
May 20, 2026

Summary
Takeaways
Insight Report
Quiz
Clinical Scorecard

Objective: To identify disparities and barriers to access high-cost therapies for childhood cancer in Canada and suggest specific health policy changes to impro

High-cost cancer therapies for children in Canada, including targeted drugs and proton beam therapy, are not universally funded.
A survey of pediatric oncology specialists revealed variable access rates to therapies like blinatumomab and larotrectinib.
Key barriers to accessing therapies included travel difficulties, economic impacts, and inconsistent funding across provinces.
Provider-reported access rates were 89% for blinatumomab and 59.2% for proton beam therapy, indicating significant disparities.
Recommendations include universal funding and establishing Canadian proton beam therapy centers to improve access.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Advertisement

Advertisement

Advertisement

About
Privacy Policy

Follow Us

Author/Creator Name

[Credentials]

[Current title or role]

Affiliations: [Institution, organization]

Specialties: Oncology Hematology

View Full Profile

Contributions:

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

Show all